Activating the Patient's Immune System to Fight Cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It is used as a therapeutic cancer vaccine, with proven ability to activate the immune system and generate tumor-specific immune responses. In phase I trials, innate and adaptive immune activation has been demonstrated both systemically and at the lesional level, which has been associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients within the next 6-12 months.

Read more on targeting cancer cells with engineered oncolytic viruses

Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS. The TG vaccine program has shown a signal of efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently being combined with pembrolizumab in a phase Ib trial in colorectal cancer.

Read more on targeting RAS mutations

Both the ONCOS and TG programs are protected by a portfolio of IP and know-how, and have the potential to generate multiple product candidates.